glp-1 options for type 2 diabetes and obesity 2025 Orforglipron, approved as Foundayo on April 1, 2026, adds another oral option chronic weight management in adults with or overweight plus at least one weight-related condition. The clinical relevance GLP-1 receptor agonists and next-generation

Aimed to quantify the rate and trajectory of weight regain and reversal of benefits after medication cessation

Beyond these two: the broader medication landscape Phentermine and tirzepatide represent two ends of the weight loss medication spectrum, but they are not the only options

Development of aortic valve disease in familial hypercholesterolemic swine: Implications for elucidating disease etiology

Gradual weight loss isnt just kinder to the skin

However, patients taking multiple antihypertensive medications should have their blood pressure monitored regularly, as excessive lowering could potentially cause symptomatic hypotension, particularly in elderly patients or those with autonomic dysfunction